BSE Live
Jan 06, 16:01Prev. Close
6363.00
Open Price
6380.35
Bid Price (Qty.)
6644.20 (100)
Offer Price (Qty.)
6659.00 (6)
NSE Live
Jan 06, 15:59Prev. Close
6363.50
Open Price
6405.50
Bid Price (Qty.)
6642.50 (386)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 26.43 | 12.95 | 12.91 | 12.91 | 12.82 | |
| Total Share Capital | 26.43 | 12.95 | 12.91 | 12.91 | 12.82 | |
| Reserves and Surplus | 1,491.38 | 1,228.43 | 848.49 | 522.50 | 327.06 | |
| Total Reserves and Surplus | 1,491.38 | 1,228.43 | 848.49 | 522.50 | 327.06 | |
| Total Shareholders Funds | 1,517.80 | 1,241.38 | 861.40 | 535.41 | 339.87 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 27.26 | 50.41 | 67.31 | 91.76 | 60.70 | |
| Deferred Tax Liabilities [Net] | 54.57 | 49.71 | 42.47 | 30.27 | 27.87 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 81.82 | 100.12 | 109.78 | 122.03 | 88.57 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 5.59 | 2.22 | 18.77 | 62.19 | 89.48 | |
| Trade Payables | 150.34 | 146.51 | 129.37 | 88.35 | 84.14 | |
| Other Current Liabilities | 14.01 | 15.55 | 27.06 | 36.11 | 31.23 | |
| Short Term Provisions | 96.45 | 48.94 | 36.56 | 2.01 | 15.76 | |
| Total Current Liabilities | 266.38 | 213.23 | 211.76 | 188.66 | 220.61 | |
| Total Capital And Liabilities | 1,866.01 | 1,554.74 | 1,182.94 | 846.11 | 649.05 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 589.84 | 589.86 | 497.06 | 381.38 | 214.87 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 23.75 | 19.50 | 63.08 | 38.25 | 80.27 | |
| Fixed Assets | 613.59 | 609.37 | 560.14 | 419.62 | 295.14 | |
| Non-Current Investments | 441.28 | 171.80 | 55.57 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 7.15 | 6.49 | 4.22 | 2.55 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 1,062.02 | 787.66 | 619.92 | 422.18 | 295.14 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 498.50 | 421.28 | 281.41 | 213.51 | 183.86 | |
| Trade Receivables | 223.20 | 266.01 | 209.45 | 161.66 | 107.44 | |
| Cash And Cash Equivalents | 16.46 | 14.79 | 14.21 | 18.34 | 10.51 | |
| Short Term Loans And Advances | 65.82 | 65.01 | 57.94 | 30.42 | 52.10 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 803.99 | 767.08 | 563.01 | 423.93 | 353.91 | |
| Total Assets | 1,866.01 | 1,554.74 | 1,182.94 | 846.11 | 649.05 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 97.21 | 86.94 | 114.67 | 117.62 | 37.82 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 13.12 | 0.15 | 0.15 | 0.15 | 0.15 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 441.29 | 171.82 | 55.57 | 0.00 | 0.00 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill